ANAPTYSBIO INC. - COM

20.55

17-April-25 16:45:00

15 minutes delayed

Stocks

+1.49

+7.82%

Today's range

18.91 - 20.75

ISIN

N/A

Source

NASDAQ

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

25 Oct 2021 16:37:00 By Nasdaq GlobeNewswire
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

02 Oct 2021 12:00:00 By Nasdaq GlobeNewswire
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 Sep 2021 16:05:00 By Nasdaq GlobeNewswire
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

17 Aug 2021 16:32:07 By Nasdaq GlobeNewswire
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

27 May 2021 16:15:00 By Nasdaq GlobeNewswire
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

04 May 2021 16:05:01 By Nasdaq GlobeNewswire
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

23 Apr 2021 10:31:07 By Nasdaq GlobeNewswire
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

22 Apr 2021 16:12:22 By Nasdaq GlobeNewswire
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

12 Apr 2021 16:00:00 By Nasdaq GlobeNewswire
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

25 Feb 2021 16:05:01 By Nasdaq GlobeNewswire
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

07 Jan 2021 16:15:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.